ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Maas Biolab LLC, the largest shareholder of NeuroVive Pharmaceutical AB of Lund, Sweden, is reducing its holdings by up to 2,207,304 shares. The NeuroVive shares will be distributed to up to 38 of its Swedish, American and international members that have elected to participate. The two-year lock-up period for distribution or sale of NeuroVive shares agreed to by Maas Biolab ends 3 October 2010, allowing this distribution.
